Loading
A phase 1/2 trial of [212Pb]Pb-MP0712 in neuroendocrine tumours, small-cell lung cancer, pancreatic ductal adenocarcinoma and bladder & urothelial cancer, run by Molecular Partners AG, now recruiting.
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors is a phase 1/2 interventional study registered as NCT07278479 by Molecular Partners AG, with 138 participants planned, started 2026-05-18 and due to reach its primary completion in 2028-09. Interventions recorded: [212Pb]Pb-MP0712.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bladder & urothelial cancer, Small-cell lung cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Molecular Partners and the tag pipeline.
Shares Molecular Partners and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/